Imatinib: new indication. Efficacy in gastrointestinal stromal tumours must be confirmed

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Gastrointestinal stromal tumours (GIST) are rare neoplasms with unpredictable malignant potential.
• Current cytotoxic agents are ineffective for inoperable or metastatic GIST, with limited patient survival.
• Imatinib, a novel tyrosine kinase inhibitor, is now indicated for GIST treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of imatinib in patients with advanced GIST.
• To assess tumour response and potential survival benefits of imatinib therapy.

Main Methods:

• A nine-month clinical trial involving 147 patients with GIST.
• Administration of oral imatinib at 400 mg or 600 mg daily.
• Monitoring for tumour regression, adverse events, and drug interactions.

Main Results:

• Partial tumour regression was observed in approximately 50% of patients treated with imatinib.
• Common adverse effects included oedema, gastrointestinal issues, skin reactions, and muscle pain.
• Severe adverse events were reported in 20% of patients, with significant drug interaction potential noted.

Conclusions:

• Imatinib represents a promising therapeutic option for advanced GIST, showing significant tumour response rates.
• Further trials are necessary to confirm imatinib's impact on overall survival and establish optimal treatment durations.
• Patient monitoring and enrollment in follow-up cohorts are crucial for refining imatinib treatment strategies.